Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands

Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands

Respiratory Syncytial Virus (RSV) poses a severe threat to infants, particularly preterm infants. Palivizumab, the standard preventive prophylaxis, is primarily utilized in high-risk newborns due to its cost. This study assessed palivizumab’s effectiveness in preventing RSV infections in predominant...

Full description

Bibliographic Details
Main Authors: Rutger M. Schepp, Joanna Kaczorowska, Pieter G. M. van Gageldonk, Elsbeth D. M. Rouers, Elisabeth A. M. Sanders, Patricia C. J. Bruijning-Verhagen, Guy A. M. Berbers
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Vaccines
Subjects:
RSV prophylaxis
palivizumab effectiveness
very preterm infants
RSV infection rates
gestational age
Online Access:https://www.mdpi.com/2076-393X/11/12/1807

Internet

https://www.mdpi.com/2076-393X/11/12/1807

Similar Items